aBsTRaCT Background
The 90-90-90 goals aim to achieve viral suppression in 90% of all HIV-infected people on antiretroviral treatment (ART), which is especially challenging in children. Global estimates of viral suppression among children in low-and middle-income countries (LMIC) are lacking. This study summarizes viral suppression rates in children on first-line ART in LMIC since the year 2000.
Methods
We searched for randomized controlled trials and observational studies and analyzed viral suppression rates among children started on ART during three time periods, based on major World Health Organization (WHO) guideline changes: early (2000) (2001) (2002) (2003) (2004) (2005) , intermediate (2006) (2007) (2008) (2009) , and current (2010 and later), using random effects meta-analysis.
Results
Seventy-two studies, reporting on 51,347 children and adolescents (<18 years), were included. After 12 months on first-line ART, viral suppression was achieved by 64.7% (95%CI 57.5-71.8) in the early, 74.2% (95%CI 70.2-78.2) in the intermediate, and 72.7% (95% 62.6-82.8) in the current time period. Rates were similar after 6 and 24 months of ART. Using an intention-to-treat analysis, 42.7% (95%CI 33.7-51.7) in the early, 45.7% 3) in the intermediate, and 62.5% ) in the current period were suppressed. Long-term follow-up data were scarce.
Conclusion
Viral suppression rates among children on ART in LMIC were low and were considerably poorer than those previously found in adults in LMIC and children in high-income countries. Little progress has been made in improving viral suppression rates over the past years. Without increased efforts to improve pediatric HIV treatment, the 90-90-90 targets for children in LMIC will not be reached.
InTRoduCTIon
Worldwide, an estimated 220,000 infants are newly infected with HIV annually 6 , and, without antiretroviral treatment (ART), >50% are expected to die before the age of two years 12 . Access to ART for HIV-infected children has increased exponentially since the beginning of this millennium, from 18,000 in 2000 to 823,000 in 2014 6 . In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) proposed the following targets to further increase the global response to the HIV epidemic: by the year 2020, 90% of people living with HIV should be aware of their status, 90% of those diagnosed should be on ART, and 90% of those on ART should be virally suppressed 109 . Children, however, constitute a difficult population in which to achieve these three targets 109 : only 40% of children born to an HIV-infected mother received an HIV test in Africa in 2012 109 , and worldwide less than a third of children living with HIV have access to ART 6 . Various studies have reported viral suppression rates in children on ART in low-and middle-income countries (LMIC) over the past years, but global summary estimates of long-term outcomes are lacking.
Achieving viral suppression in children on ART is challenging, because of various reasons, including variability in children's weight and antiretroviral pharmacokinetics 110 ; pre-treatment HIV drug resistance due to prior exposure to drugs as part of prevention of mother-to-child transmission (PMTCT) interventions 104, 111 ; and, adherence problems due to poor palatability of drugs or dependence on caregivers who are frequently ill themselves 112 . Evaluation of pediatric HIV programs in LMIC can provide benchmarks for treatment outcomes in children and adolescents and contribute to the development of more effective pediatric HIV treatment guidelines for LMIC. This systematic review and meta-analysis aims to summarize the long-term viral response to first-line ART among children and adolescents living in LMIC and to assess the progress towards the 90% target since the beginning of this millennium, in the context of evolving HIV prevention and treatment guidelines.
MeTHods search
This study was performed in accordance with the PRISMA statement for reporting systematic reviews and meta-analyses 113 . The systematic review protocol is provided in Supplement I. A search was conducted to find articles on viral outcomes in HIV-infected children 90 and adolescents < 18 years of age living in LMIC 114 , in the first five years on first-line ART, published until May 2015, in English, French and 
study selection and data extraction
Cohort studies, cross-sectional studies and randomized controlled trials were included. Participants of the study had to be <18 years of age at treatment initiation, HIV-1 infected, and starting first-line treatment in LMIC. We included studies reporting on pre-defined six-monthly time points up to 60 months after treatment initiation. For studies reporting a suppression rate at a median time after treatment initiation, we only included these if the interquartile range was ≤12 months. Two reviewers performed selection of studies independently and any disagreement was resolved by discussion between both. Data were extracted using a data extraction form designed for this purpose in MS Access 2013®. Data on the following variables were extracted from each article: country, study design, study period, percentage female participants, median age at first-line ART initiation, prior PMTCT exposure, PI-or NNRTI-based first-line regimen, number of participants at ART initiation, attrition during follow-up, number of participants with viral load (VL) measurement at pre-defined six-monthly time point, number of participants with viral suppression at that time point, and VL threshold used to define viral suppression. The viral suppression threshold used in each study was pooled into three categories: <50 cps/ ml, <400 cps/ml or <1000 cps/ml. Children who had viral suppression at <50 cps/ml were also included in the <400 cps/ml and <1000 cps/ml analyses, and children suppressed at <400 cps/ml were also included in the <1000 cps/ml analysis. When reported, data extraction was done separately for participants on PI-or NNRTI-based regimens, and for participants with or without PMTCT exposure. As we expected the majority of studies to be observational studies rather than randomized controlled trials, we assessed the study quality and risk of bias using an adapted version of the Newcastle Ottowa Scale 115 (Supplement III). 91 data analysis Viral suppression rates were analyzed in three time periods, based on the WHO recommendations on PMTCT and pediatric HIV treatment in the median year of ART initiation in each study (Table 1 ). The early time period (2000) (2001) (2002) (2003) (2004) (2005) is characterized by the use of a single drug for PMTCT and non-nucleoside reverse transcriptase inhibitor (NNRTI)based first-line ART for all children, the intermediate time period is characterized by an extended regimen of prophylactic antiretroviral drugs for mother and child (option A) and no change in first-line ART recommendations, and the current time period is characterized by the introduction of maternal triple therapy for PMTCT and protease inhibitor (PI)-based treatment for children <3 years of age.
In the primary analysis, we calculated the proportion of children with viral suppression by dividing the number of children with VL<1000cps/ml by the number of children who were on treatment and had VL results at that time point. The analyses were conducted separately for each six-monthly time point. A study was included in the analysis of multiple time points if suppression rates at more than one time point were reported. Summary estimates of viral suppression were analyzed using random effects meta-analysis, because of the heterogenic nature of the included studies. The variance of the raw proportions was stabilized using a Freeman-Tukey arcsine square root transformation and was subsequently back-transformed to the original scale. Heterogeneity of outcomes was assessed through calculation of I 2 -statistics. Meta-regression analysis was used to estimate the association between time period of ART initiation and the proportion of children with viral suppression.
In addition, we conducted an intention-to-treat analysis, in which we calculated the viral suppression rate by dividing the number of children with VL<1000 cps/ml at 12 months by the number of children who had started first-line ART. Using this approach, we considered all children who did not have a VL result, either because of death, loss to follow-up, transfer out or a missed clinic visit, as experiencing viral failure. Additionally, we conducted sensitivity analyses in which we used a threshold of <400 cps/ml and <50 cps/ml to define viral suppression. Finally, we conducted sensitivity analyses in which we: 1) excluded studies with a median age <3 years; 2) excluded studies with a median age ≥10 years; 3) only included studies from sub-Saharan Africa; 4) only included observational studies; and, 5) only included studies with a maximum score on the adapted Newcastle Ottowa Scale. All data analyses were performed using Stata 12.1® (StataCorp. 2011. College Station, TX: StataCorp LP). 
ResulTs study characteristics
The study selection process is shown in Figure 1 . We included 72 studies, reporting on a total of 51,347 children. The median year of ART initiation in each study ranged from 2000 to 2011. Thirty studies were conducted in the early time period (2000) (2001) (2002) (2003) (2004) (2005) , 35 studies were conducted in the intermediate period (2006) (2007) (2008) (2009) , and seven in the current period (2010 and later). The median age at ART initiation of children in the included studies ranged from 0.1 to 16.4 years; 17 studies reported on children with a median age of <3 years and 3 studies on children with a median age ≥10 years (Table 2) . A complete overview of all studies is provided in Supplement IV.
Figure 1. Flow diagram of systematic review and study selection

Viral suppression after 6 to 60 months on first-line aRT
After 6 months on first-line ART, a pooled proportion of 62.2% (95%CI 55.0-69.3, total n=5,448) had viral suppression in the early, 74.3% (95%CI 69.7-78.9, total n=12,655) in the intermediate, and 80.3% (95%CI 70.0-90.6, total n=627) in the current period, p=0.03 ( Figure 2 Figure 4 ). Only nine studies reported viral outcomes after more than 24 months of ART. Viral suppression rates at 36, 48 and 60 months of first-line ART are shown in Table 3 .
Intention-to-treat analysis and sensitivity analyses
We conducted an intention-to-treat analysis at 12 months after first-line ART initiation. A pooled proportion of 42.7% (95%CI 33.7-51.7) in the early, 45.7% (95%CI 33.2-58.3) Using a threshold of VL<50 cps/ml, these rates were 55.3% (95%CI 39.5-71.0), 51.6% (95%CI 40.3-63.0), and 65.5% (95%CI 38.4-92.7), respectively, p=0.568 ( Figure 5 ). Additionally, we conducted sensitivity analyses excluding children aged <3 years; excluding adolescents aged ≥10 years; only including studies conducted in sub-Saharan Africa; only including observational studies; or only studies with a Newcastle Ottowa Scale score of 6. These analyses yielded results similar to our primary analysis ( Figure 6 ). 
Figure 5. Proportion of children with viral suppression after 12 months of first-line antiretroviral treatment, using different definitions of viral suppression
The primary analysis shows the proportion of children with a viral load<1000 cps/ml out of all children in care and with a viral load measurement after 12 months; the intention-to-treat analysis shows the proportion of children with a viral load<1000 cps/ml out of all children who started first-line treatment; the threshold VL<400 cps/ml shows the proportion of children with a viral load <400 cps/ml out of all children in care and with a viral load measurement after 12 months; the threshold VL<50 cps/ml shows the proportion of children with a viral load <50 cps/ml out of all children in care and with a viral load measurement after 12 months. Early: ART initiated between 2000 and 2005; Intermediate: ART initiated between 2006 and 2009; Current: ART initiated in 2010 or later. Error bars represent 95% confidence intervals dIsCussIon In this systematic review and meta-analysis, we evaluated the viral response to first-line ART over the past 15 years in children living in LMIC. Viral suppression rates were 60-75% in most analyses and have only marginally improved since the beginning of this millennium. Although suppression rates after six months of ART in the most recent time period were significantly higher than in the early time periods, this effect was not seen after 12 and 24 months of ART. The suppression rates we found are considerably poorer than those reported in a meta-analysis among adults in LMIC, which was previously conducted by our research group using the same methodology and similar inclusion criteria 116 . In this analysis, including studies with a median year of ART initiation between 2001 and 2010, approximately 85% had viral suppression in the first two years of first-line ART.
Our outcomes are also worse compared to the suppression rates of ≥90% found in HIVinfected children in high-income countries 71, 92, 117 . A study among Dutch HIV-infected children previously found that the proportion of children with viral suppression increased from ~50% in 2000 to ~90% in 2012 117 . Our data show that this dramatic improvement over time in a high-income country has not yet been achieved in LMIC. Viral suppression rates were very low using an intention-to-treat approach, as only 43% in the early and 63% in the current period were in care, on treatment and virally suppressed after 12 months of ART. These rates are again lower than the intention-to-treat results of the adult meta-analysis, in which 67-75% had suppression in the first year of first-line ART 116 . The low rate of children who were on treatment and had viral suppression after a year of treatment reflects the challenges of keeping children in care in routine HIV treatment programs in LMIC. Previous studies have identified younger age, malnutrition, and advanced stage of disease as risk factors for attrition among children in ART programs in LMIC 107, 118, 119 . The scarcity of data after two years of follow-up might be another indication of the difficulties of retaining children on long-term treatment. We set out to analyze viral suppression rates up to five years after first-line ART initiation, but found that only nine studies reported on outcomes after more than two years. Interestingly, suppression rates after 24 months were higher than the 6-and 12-month measurements. This result might be explained by the fact that studies with a longer follow-up are generally performed at better-equipped study sites with more resources available and therefore may obtain better study outcomes.
Our primary analysis used a threshold of VL<1000 cps/ml to define viral suppression, in line with the 90-90-90 targets and the WHO definition of viral failure 20,109 . In our sensitivity analysis, viral suppression rates using a threshold of VL<400 cps/ml were similar to the outcomes of the primary analysis, but, using a threshold of VL<50 cps/ml, suppression rates dropped to 52-66%. This suggests that part of the children who are considered to be suppressed, have low-level viremia with VL levels between 50 and 400 cps/ml. In these children with ongoing viral replication, the risk of development of drug resistant mutations and subsequent treatment failure is increased 120 . Careful monitoring of this group would be needed to prevent progression to viral failure.
strengths and limitations
A major strength of our study is the fact that it provides one of the largest and most comprehensive meta-analyses of viral outcomes in HIV-infected children in LMIC to date. Our findings were robust across several sensitivity analyses. We aimed to include all available data on this topic and included observational studies and randomized controlled trials, studies in which viral suppression was the primary outcome and those in which it was a secondary finding. We used random-effects meta-analysis to account for the heterogene-ity of data resulting from this approach. Our study also has some potential limitations. First, we performed analyses separately for three different time periods based on the WHO guidelines at that time, although studies included in a certain time period do not necessarily reflect the guidelines of that period, as implementation of guidelines might be delayed. We aimed to collect viral suppression rates separately for PI-and NNRTI-treated children and PMTCT-exposed and unexposed children, but only few studies reported outcomes separately for these subgroups and data were insufficient to conduct comparative analyses. Furthermore, it was not possible to correct for other relevant characteristics, such as age, clinical or immunological status, or level of adherence. Including study averages of these data would have introduced the risk of ecological fallacy as we only collected study-level data and no individual data 121 . We planned to conduct separate analyses for children and adolescents, as HIV treatment in adolescents is known to be particularly challenging and to have poorer outcomes than in children 122 . However, only three studies included children with a median age ≥10 years of age; excluding these studies in a sensitivity analysis yielded similar results to our primary analysis. As most studies did not specify the reasons why children did not have a VL result at a scheduled time point, we used a very strict definition of viral suppression, considering all children with missing VL results as having viral failure. Our intention-to-treat analysis might therefore underestimate the actual suppression rate.
Implications
Over the past decades, pediatric HIV has received less research attention and less funding compared to adult infection, which has been reason to consider pediatric HIV a neglected disease 31 . This lack of attention is especially concerning because HIV treatment in children brings along some additional challenges compared to adult treatment: the limited availability of pediatric drug formulations and changing weight and pharmacokinetics in children make drug supply, dosing and administration for children more difficult; previous exposure to PMTCT could give rise to pre-treatment HIV drug resistance increasing the risk of treatment failure; and, a child's dependence on its caregivers might lead to adherence and retention problems 112 . The proportion of children with viral suppression was 60-75% in most analyses. These findings are alarming and call for immediate action to be taken if the final 90 of the 90-90-90 targets in this population is to be reached. First, initiation of PI-based treatment in all young children is an evidence based strategy to improve suppression rates 25, 26 . Although recommended by the WHO since 2013 20 , many LMIC have not implemented this strategy because PIs are more costly than NNRTIs and require refrigeration. In order to treat all children < 3 years with a PI-based regimen, substantial financial and logistic barriers for LMIC to implement this strategy must be overcome. Development of heat-stable drugs and cost-reduction of antiretroviral drugs for LMIC are important steps to increase access to PI-based treatment. Second, VL monitoring in children on ART is important to timely detect treatment failure and switch to second-line ART, as CD4 count has been shown to be a poor indicator of treatment failure in children 123, 124 . Implementation of VL monitoring for this population in LMIC should be a priority. Third, studies assessing long-term outcomes of children on ART in LMIC are currently lacking. The scarcity of data on viral outcomes beyond two years of treatment indicates that this in an area of understudy. Especially in children, who have a full life ahead and will require ART for many decades, information on long-term treatment outcomes is needed to preserve adequate ART provision for the rest of their lives. Finally, treatment adherence in children is often problematic, because of poor palatability of drugs such as LPV/r, dependence on caregivers for younger children, and fear of stigmatization for older children 125, 126 . Adherence support programs should be an integral part of pediatric HIV treatment in order to improve treatment outcomes of children in LMIC.
In conclusion, we report viral suppression rates among children in LMIC to be low and well below those found in adults in LMIC and in children in high-income countries. Little improvement in viral treatment outcomes has been witnessed over the past ten years. To achieve the 90-90-90 targets by 2020, accelerated efforts are fundamental to improve HIV treatment in this vulnerable population. Furthermore, the scarcity of data on virological outcomes after more than two years of follow-up reveals an area of profound understudy. Research into long-term treatment outcomes is essential in this population of children who will need adequate treatment for the rest of their lives. Although the ultimate goal of the global HIV response would be the complete elimination of pediatric HIV infection, measures to improve HIV care for 2.6 million 127 children currently living with HIV worldwide are urgently needed.
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